US2005240012A1PendingUtilityA1

Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity

59
Individually held — no corporate assignee on recordPriority: Mar 7, 1994Filed: Feb 22, 2005Published: Oct 27, 2005
Est. expiryMar 7, 2014(expired)· nominal 20-yr term from priority
Inventors:Edward D. BallMichael W. Fanger
A61K 47/6813A61K 38/00C07K 16/283A61K 39/395C07K 2319/00A61K 47/6857C07K 7/086C07K 14/595C07K 2317/732A61K 47/6879A61K 47/68
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Bispecific molecules comprising a target cell specific ligand and an effector cell specific antibody or functional antibody fragment are disclosed.

Claims

exact text as granted — not AI-modified
1 - 24 . (canceled)  
   
   
       25 . A bispecific molecule comprising an autocrine growth factor specific for a tumor cell and an antibody or antigen binding fragment thereof which binds to FcγRI on an effector cell at a site that is not inhibited by endogenous immunoglobulin.  
   
   
       26 . The bispecific molecule of  claim 25 , wherein the tumor cell is a human small-cell lung carcinoma cell.  
   
   
       27 . The bispecific molecule of  claim 26 , wherein the autocrine growth factor binds to the gastrin-releasing peptide receptor of the human small-cell lung carcinoma cell.  
   
   
       28 . The bispecific molecule of  claim 27 , wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin-releasing peptide.

Join the waitlist — get patent alerts

Track US2005240012A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.